


17V

89823.1

PATENT

13374P3-CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wermeling Examiner: To be assigned
Serial No.: 10/647,789 Group Art Unit: 1615
Filed: August 25, 2003
For: Intranasal Opioid Compositions
Customer No.:

23719

PATENT TRADEMARK OFFICE

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

May 12, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. Applicants do not admit that the references are "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants' duty to disclose all information of which they are aware and believe relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Signature)

(Printed Name of Person Signing Certificate)

(Date)

[Handwritten Signature]
[Handwritten Name: Silvia Gonzalez]
[Handwritten Date: May 12, 2005]


Applicant: Wermeling
Serial No.: 10/647789
Filed: 8/25/2003
Information Disclosure Statement – Page 2

I. U.S. PATENT DOCUMENTS

<u>Patent No.</u>	<u>Date Issued</u>	<u>Title</u>
4,782,047 to Benjamin et al.	Nov. 1, 1988	Aqueous Steroid Formulation For Nasal Administration
5,637,314 to Sharpe et al.	June 10, 1997	Topical and Systemic Application of Buspirone or Derivatives Thereof for Treating Atopic Dermatitis


Because no action has been taken on the merits, Applicants submit that no fee is due at this time. However, if a fee is deemed necessary, please charge Deposit Account No. 11-0171.

Respectfully submitted,



William D. Schmidt
Registration No.: 39,492
Attorney for Applicant

Kalow & Springut LLP
(212) 813-1600

 <p style="text-align: center;">INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>	Docket Number (Optional) 13374P3-CIP	Application Number 10/647,789
	Applicant(s) WERMELING	
	Filing Date August 25, 2003	Group Art Unit 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,782,047	11-01-1988	Benjamin et al			
		5,637,314	06-10-1997	Sharpe et al			

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.